Biblio

Author Title Type [ Year(Desc)]
Filters: Author is Pawarode, Attaphol  [Clear All Filters]
2014
Gatza E, Braun T, Levine JE, Ferrara JLM, Zhao S, Wang T, Chang L, Harris A, Pawarode A, Kitko C, et al. Etanercept plus topical corticosteroids as initial therapy for grade 1 acute graft-versus-host disease after allogeneic hematopoietic cell transplant. Biol Blood Marrow Transplant. 2014.
2015
Kitko CL, Braun T, Couriel DR, Choi SW, Connelly J, Hoffmann S, Goldstein S, Magenau J, Pawarode A, Reddy P, et al. Combination Therapy for GVHD Prophylaxis with Etanercept and Extracorporeal Photopheresis: Results of a Phase II Clinical Trial. Biol Blood Marrow Transplant. 2015.
Zhou C, Chan H-P, Dong Q, Couriel DR, Pawarode A, Hadjiiski LM, Wei J. Quantitative Analysis of MR Imaging to Assess Treatment Response for Patients with Multiple Myeloma by Using Dynamic Intensity Entropy Transformation: A Preliminary Study. Radiology. 2015:142804.
2020
Mehta RS, Holtan SG, Wang T, Hemmer MT, Spellman SR, Arora M, Couriel DR, Alousi AM, Pidala J, Abdel-Azim H, et al. Composite GRFS and CRFS Outcomes After Adult Alternative Donor HCT. J Clin Oncol. 2020:JCO1900396.
Bejanyan N, Zhang M, Bo-Subait K, Brunstein C, Wang H, Warlick ED, Giralt S, Nishihori T, Martino R, Passweg J, et al. Myeloablative Conditioning for Allogeneic Transplantation Results in Superior Disease-Free Survival for Acute Myeloid Leukemia and Myelodysplastic Syndromes with Low/Intermediate, but not High Disease Risk Index: A CIBMTR Study: Superior DFS with MAC comp. Biol Blood Marrow Transplant. 2020.
Nazha A, Hu Z-H, Wang T, R Lindsley C, Abdel-Azim H, Aljurf M, Bacher U, Bashey A, Cahn J-Y, Cerny J, et al. A Personalized Prediction Model for Outcomes after Allogeneic Hematopoietic Cell Transplant in Myelodysplastic Syndromes Patients. Biol Blood Marrow Transplant. 2020.
Zhou Z, Nath R, Cerny J, Wang H-L, Zhang M-J, Abdel-Azim H, Agrawal V, Ahmed G, A Al-Homsi S, Aljurf M, et al. Reduced intensity conditioning for acute myeloid leukemia using melphalan- vs busulfan-based regimens: a CIBMTR report. Blood Adv. 2020;4(13):3180-3190.
Gowin K, Ballen K, Ahn KWoo, Hu Z-H, Ali H, Arcasoy MO, Devlin R, Coakley M, Gerds AT, Green M, et al. Survival following allogeneic transplant in patients with myelofibrosis. Blood Adv. 2020;4(9):1965-1973.
2021
Oran B, Ahn KWoo, Fretham C, Beitinjaneh A, Bashey A, Pawarode A, Wirk B, Scott BL, Savani BN, Bredeson C, et al. Fludarabine and Melphalan Compared with Reduced Doses of Busulfan and Fludarabine Improves Transplant Outcomes in Older MDS Patients. Transplant Cell Ther. 2021.
Riedell PA, Hamadani M, Ahn KW, Litovich C, Murthy GSubramania, Locke FL, Brunstein CG, Merryman RW, Stiff PJ, Pawarode A, et al. Outcomes and Utilization Trends of Front-Line Autologous Hematopoietic Cell Transplantation for Mantle Cell Lymphoma. Transplant Cell Ther. 2021.
2022
Murthy HS, Ahn KWoo, Estrada-Merly N, Alkhateeb HB, Bal S, Kharfan-Dabaja MA, Dholaria B, Foss F, Gowda L, Jagadeesh D, et al. Outcomes of Allogeneic Hematopoietic Cell Transplantation in T-cell Prolymphocytic Leukemia: A Contemporary Analysis from the Center for International Blood and Marrow Transplant Research. Transplant Cell Ther. 2022.
Coda J, Raser K, Anand SM, Ghosh M, Gregg K, Li J, Maciejewski JJ, Pawarode A, Riwes MM, Tillman C, et al. Pneumocystis jirovecii Infection in autologous hematopoietic stem cell transplant recipients. Bone Marrow Transplant. 2022.
2023
Riwes MM, Golob JL, Magenau J, Shan M, Dick G, Braun T, Schmidt TM, Pawarode A, Anand S, Ghosh M, et al. Feasibility of a dietary intervention to modify gut microbial metabolism in patients with hematopoietic stem cell transplantation. Nat Med. 2023.
Ragon BKnick, Shah MVinod, D'Souza A, Estrada-Merly N, Gowda L, George G, DeLima M, Hashmi S, Kharfan-Dabaja MA, Majhail NS, et al. Impact of Second Primary Malignancy Post-Autologous Transplantation on Outcomes of Multiple Myeloma: A CIBMTR Analysis. Blood Adv. 2023.
Magenau JM, Jaglowski SM, Uberti J, Farag SS, Riwes MMansour, Pawarode A, Anand S, Ghosh M, Maciejewski J, Braun TM, et al. A Phase 2 Trial of CD24Fc for Prevention of Graft-vs-Host Disease. Blood. 2023.
Tamari R, McLornan DP, Ahn KWoo, Estrada-Merly N, Hernández-Boluda JCarlos, Giralt SA, Palmer JM, Gale RPeter, DeFilipp Z, Marks D, et al. A Simple Prognostic System in Myelofibrosis Patients Undergoing Allogeneic Stem Cell Transplant: A CIBMTR/EBMT analysis. Blood Adv. 2023.